The mechanism of a synergistic toxicity of 6,6'-dimycoloyl-a,a'-D-trehalose (cord factor) and 2,3,6,6'-tetraacyl-a,a'-D-trehalose 2'-sulfate (sulfolipid I) for mice was studied. Sulfolipid I was entirely nontoxic, but it markedly accelerated the lethal toxicity of cord factor for mice. In vivo, sulfolipid I affected neither respiration nor accompanying phosphorylation of mouse liver mitochondria, whereas in vitro, it induced a swelling and disruption of mitochondrial membranes and strongly inhibited mitochondrial oxidative phosphorylation. The effect of sulfolipid I on mitochondrial structure and function in vitro was neutralized by bovine serum albumin and various animal sera, whereas that of cord factor and cord factor plus sulfolipid I was not prevented by bovine serum albumin. The simultaneous injection of cord factor and sulfolipid I caused an intensive fragmentation of mitochondria and a marked decrease in respiratory and phosphorylative activity in mitochondria. These data indicate that sulfolipid I can achieve an effective attack on mitochondria in combination with cord factor in vivo and induces heavier damage in mitochondrial structure and function than that produced by cord factor alone.
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Sulfolipid I (SL-I), the principal sulfatide of virulent human Mycobacterium tuberculosis strain H37Rv (3) , has been identified as a 2,3,6,6'-tetraacyl-ca,a'-D-trehalose 2'-sulfate (4) . More recently, the structures of the acyl substituents on the trehalose sulfate core were characterized, and the chemical constitution of SL-I is now well established (6) . Despite the detailed clarification of its chemical structure, neither its biological activity nor its role in the pathogenesis of tuberculosis of the mycobacterial sulfatides is yet known (2, 5, 14) .
Because of its molecular size and constitution, SL-I is closely related in structure to cord factor (6, 6 '-dimycoloyl-a,a'-D-trehalose [16] ), a toxic glycolipid of M. tuberculosis. Early animal tests (4) gave no evidence that either SL-I or its desulfated analogue, even at high dosages, possesses the animal toxicity characteristic of cord factor. However, mice that had been injected with SL-I or desulfated SL-I in oil were subsequently found much more susceptible to cord factor intoxication than control mice that had received only the oil vehicle. In normal mice, combinations of SL-I (or desulfated SL-I) with cord factor were seen to be nearly an order of magnitude more toxic than an equivalent dose of cord factor alone; other, as yet incompletely characterized mycobacterial trehalose glycolipids also promoted the toxicity of cord factor, but to a lesser degree (5; M. B. Goren, unpublished data).
We have therefore sought additional evidence and a mechanistic clarification of this apparently synergistic activity of the SL substances with cord factor. The study described in this paper confirms and extends the scope of the earlier observations: it demonstrates that, in vivo, SL-I lacks either mouse toxicity or inhibitory action on oxidative phosphorylation in mouse liver mitochondria. However, in vitro, isolated mitochondria are attacked by SL-I with a resultant pronounced structural and functional damage. The studies further show that in vivo or in vitro SL-I and cord factor act synergistically both in terms of mouse toxicity and in attack on mitochondrial structure and function. The mechanism of this synergistic action was studied in some detail. KATO 
RESULTS
Synergism of cord factor and SL-I in mouse toxicity. No toxic effect was seen in mice injected intraperitoneally with 100 to 500 jig of SL-I ( wasting symptoms than the latter. SL-I enhanced the toxicity of cord factor even when both lipids were injected separately and by different routes (Fig. 2) . Intraperitoneally injected SL-I also accelerated the toxicity of cord factor that was injected intravenously or subcutaneously (not shown). SL-I neither lent toxicity to mycolic acids or to the nontoxic cord factor analogue, 6,x-di-(3'-acetoxy, x-methoxymycoloyl)-N-acetyl-D-glucosamine, nor enhanced the toxicity of two toxic cord factor analogues, methyl-6-mycoloyl-a-D-glucopyranoside and methyl-6-mycoloyl-f,-D-glucopyranoside ( Table 1 (Table 2) . However, as in the case of cord factor (12) tion of mitochondrial oxidative phosphorylation at a lower concentration range than cord factor (12) . It was further demonstrated that respiratory control was completely lost in both succinate and reduced nicotinamide adenine dinucleotide pathways, that phosphorylation at both coupling sites II and III was affected ( Table 3) , and that mitochondrial adenosine triphosphatase was markedly stimulated by the above range of concentration of SL-I (Table 4 ). These data indicate that SL-I is a potent inhibitor of mitochondrial oxidative phosphorylation in vitro and that the mode of interaction of SL-I with the mitochondrial electron transport chain is different from that of cord factor (12) .
Effect of SL-I on mitochondrial oxidative phosphorylation in vivo. Despite the above findings that SL-I was a powerful inhibitor of oxidative phosphorylation when it was preincubated with the bare mitochondria in vitro, the intraperitoneal injection of 200 jig of SL-I in oil affected neither respiration nor accompanying (Table 5) . Five intraperitoneal injections of 200 ug of SL-I were also without effect. These data are consistent with the complete lack of mouse toxicity of SL-I.
Swelling of mitochondria induced by SL-I in vitro. SL-I induced in vitro a dose-dependent swelling of mitochondria. With increasing concentration of SL-I, reversibility of swelling induced by the addition of adenosine triphosphate, magnesium ion, and bovine serum albumin (BSA) was lost, indicating that the mitochondrial membranes were irreversibly disrupted by SL-I. However, SL-I did not cause any swelling of mitochondria when the medium contained 2 mg of BSA per ml. Mouse, rabbit, and fetal calf serum at a concentration of 2% showed the same effect in protecting mitochondria from the action of SL-I. The incorporation of BSA in the preincubation medium reduced the inhibitory action of SL-I on mitochondrial oxidative phosphorylation (Table 6 ). In contrast to this, the action of cord factor to induce mitochondrial swelling was not prevented by BSA (11) . Cord factor affected oxidative phos- 5 min at 20 C. The following reagents were added at 0 min: BSA (2 mg/ml) or, at 15 min (arrow), adenosine triphosphate (5 mM); BSA (2 mg/ml); MgCl2 (3 mM). more markedly by the combination of cord factor and SL-I than by either cord factor or SL-I alone (Table 8 ). This synergistic action of cord factor and SL-I was not prevented by the presence of BSA in the preincubation medium, whereas the effect of SL-I was partially neutralized by BSA ( Table 9 ). The synergistic action of cord factor and SL-I was further demonstrated in the in vivo experiments. When a relatively small amount (25 ,g) of cord factor was injected intraperitoneally into mice, either the rate of succinate oxidation and the efficiency of phosphorylation (Table 10) or the structural components in mitochondria (Table 11 ) was barely affected. The injection of 25 Mg of SL-I was entirely without effect. However, the liver mitochondria isolated from mice which received the combined injection of cord factor and SL-I (25 ,ug plus 25 Mg) showed a significant decrease in both respiratory and phosphorylative activity (Table 10) . A marked decrease in the mitochondrial structural components and a concomitant increase in these components in the light-particle fraction, which was found to be rich in fragmented mitochondria (9) , after the combined injection of cord factor and SL-I (Table  11) indicate that SL-I can achieve an effective attack on mitochondrial membrane systems in vivo in the presence of cord factor, and thus both glycolipids synergistically damage the structure and function of mitochondria.
DISCUSSION
These results confirm an earlier observation (4) that SL-I of M. tuberculosis H37Rv is not toxic for mice by the intraperitoneal injections bExpressed as in Table 6 . a Mitochondria were preincubated with either sulfolipid I (SL-I), cord factor, or SL-I + cord factor for 15 min at 20 C with or without bovine serum albumin (BSA) before addition to the assay medium. b Expressed as in Table 6 . tems of mitochondria, whereas the structural damage induced by cord factor was partial (11) .
In sharp contrast with the above in vitro effect, in vivo, SL-I was entirely without effect on mitochondrial structure and function. We have presumed, therefore, at least three possible mechanisms of the apparent nontoxicity and the lack of in vivo action of SL-I. First, SL-I action is neutralized by some physiologically occurring agents such as serum proteins; second, SL-I affects bare mitochondria but it can not pass through cell membrane and therefore does not attack intracellular mitochondria; and third, SL-I is rapidly decomposed in vivo. Before testing the last two possibilities, we first examined the neutralizing effect of either BSA or various animal sera on the action of SL-I to induce mitochondrial swelling. It was found that SL-I lost its ability to cause swelling and to inhibit oxidative phosphorylation in mitochondria when the preincubation medium contained BSA. SL-I seems to bind to basic sites of BSA by its sulfate group. The mechanism of this neutralizing effect of BSA against the action of SL-I on mitochondria is under investigation. Studies on the other possible mechanisms of the lack of animal toxicity of SL-I are also in progress.
This paper further shows that the action of cord factor on mitochondrial oxidative phosphorylation was not prevented by BSA; that the neutralizing effect of BSA on SL-I action was relieved by the presence of cord factor in the incubation medium; and that both lipids synergistically damaged mitochondrial structure and function in vivo. It appears from these results that SL-I is devoid of toxicity because its action on mitochondrial membrane systems is neutralized by serum proteins, whereas cord factor is toxic since its effect on mitochondria is not prevented in the in vivo environment. In concert with cord factor, SL-I became accessible to the mitochondrial membrane systems in vivo and thus both lipids severely damaged the structure and function of mitochondria. The increased activity could be caused by the formation of a more monstrous, and hence less digestible or less metabolizable, glycolipid complex by a micellar association. It appears also possible that SL-I could attack, even in the presence of BSA, the mitochondria that were primarily and partially damaged by cord factor. This seems, partly at least, the biochemical basis of the synergistic toxicity of cord factor and SL-I for mice. It may be assumed from these results that the above two trehalose glycolipids with defined chemical structure play, in combination, an important role in the pathogenicity of M. tuberculosis.
